Zantac
In October 2019, a class-action lawsuit was filed against Sanofi for allegedly misleadingly marketing the over-the-counter heartburn medication Zantac as safe when, according to plaintiffs, the medicine contains dangerously high…
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
In October 2019, a class-action lawsuit was filed against Sanofi for allegedly misleadingly marketing the over-the-counter heartburn medication Zantac as safe when, according to plaintiffs, the medicine contains dangerously high…
Verdict comes nine years after TINA.org alerted regulator to supplement’s unsubstantiated health claims.
Grab your bag now, before Dina & Mita do
Regulators have a beef with company’s climate pledge.
Consumers need to be wary of undisclosed incentivized reviews.
Why TINA.org supports FTC’s proposed changes to COPPA Rule but pushes for more.